A recent study by scientists at the University of Edinburgh offers a dual solution to the sustainability challenges of both plastic pollution and traditional pharmaceutical manufacturing. In a groundbreaking study published in the scientific journal Nature Sustainability, researchers successfully used genetically engineered bacteria to transform everyday PET plastic waste into levodopa (L-DOPA), a frontline drug used in the treatment of Parkinson’s disease, marking a global first in bio-upcycling.
Recycling the approximately 50 million tonnes of polyethylene terephthalate (PET) waste generated worldwide each year is one of modern industry’s greatest challenges. Widely used in food and beverage packaging and derived from petroleum, this plastic can only be processed with limited efficiency using traditional methods, leaving a significant portion to end up in landfills. However, Professor Stephen Wallace and his research team have developed an entirely new biological upcycling (bio-upcycling) method to address this crisis.
The Mechanism of Biological Transformation
During their laboratory experiments, the researchers utilized genetically modified Escherichia coli (E. coli) bacteria, specifically the E. coli BL21(DE3) strain. As the first step in the procedure, the PET waste was chemically depolymerized, breaking the plastic down into its fundamental chemical building block, terephthalic acid (TPA).
The true biological feat followed: the scientists engineered a newly designed, four-step biosynthetic pathway encoded by seven genes. Through a series of enzymatic reactions taking place in mild, aqueous conditions, the modified bacteria directly converted the terephthalic acid molecules into the active pharmaceutical ingredient, L-DOPA. To optimize the process, the researchers divided the workflow into a co-culture of two collaborating microbial strains, overcoming biochemical hurdles such as cellular enzyme inhibition. Tests also revealed that the addition of a transporter called TpaK significantly improved the conversion process even at a neutral pH.
Quantified Results and Conversion Efficiency
The scientific publication provided highly precise quantitative data regarding the performance of this new technology:
-
Using the optimized, two-step workflow, the transformation of TPA derived from industrial film waste was achieved with an 84 percent conversion efficiency.
-
The system reached an outstanding L-DOPA titer (concentration) of 5.0 g/L (5 grams per liter).
-
In a specific experiment conducted on a real, post-consumer PET bottle, the procedure yielded a 49 percent conversion rate, producing 193 milligrams of isolated solid L-DOPA. This quantity alone is sufficient to cover multiple clinical doses typically administered in the early stages of Parkinson’s disease.
Sustainability and Industrial Perspectives
Traditional pharmaceutical manufacturing relies heavily on finite fossil fuels and petrochemical-based feedstocks. In contrast, the method developed at the University of Edinburgh utilizes environmentally polluting plastic waste as a massive, previously untapped carbon source.
Following this successful laboratory proof-of-concept, the research team’s primary objective is to ensure the industrial scalability of the technology. This involves further fine-tuning of the process, as well as a comprehensive industrial assessment of the method’s environmental and economic performance. According to experts, this innovation could pave the way for a new biological manufacturing industry capable of sustainably synthesizing not only pharmaceuticals but also industrial chemicals, fragrances, and cosmetics directly from trash in the future.
Official Source and Reference:
-
Original Scientific Publication: Royer, B., Era, Y., Valenzuela-Ortega, M. et al. (2026). Microbial upcycling of plastic waste to levodopa. Nature Sustainability. DOI: 10.1038/s41893-026-01785-z
